CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+11.29%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.27B
AUM Growth
+$2.27B
(-0.36%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-5.36%
Top 10 Holdings %
Top 10 Hldgs %
41.58%
Holding
96
New
16
Increased
10
Reduced
55
Closed
6
Top Buys
| 1 |
Immunovant
IMVT
|
$57.6M |
| 2 |
ALX Oncology
ALXO
|
$36M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$35.5M |
| 4 |
Zymeworks
ZYME
|
$27.9M |
| 5 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$23.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 91.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $213M | 8.2% | 2,442,297 -295,000 | -11% | -$25.8M |
|
|
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $166M | 6.4% | 3,379,373 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $91.9M | 3.53% | 2,640,177 +3,516 | +0.1% | +$122K |
|
4
BridgeBio Pharma
BBIO
$9.89B
| $85M | 3.27% | 2,265,762 -325,000 | -13% | -$12.2M |
|
|
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
| $76.7M | 2.95% | 1,400,000 -300,000 | -18% | -$16.4M |
|
6
Avidity Biosciences
RNA
$5.99B
| $69.5M | 2.67% | 2,514,546 -1 | -0% | -$28 |
|
|
SRNE
7
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $66.9M | 2.57% | 6,000,000 -500,000 | -8% | -$5.58M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $61.3M | 2.36% | 450,000 -150,000 | -25% | -$20.4M |
|
|
9
Immunovant
IMVT
$2.56B
| $57.6M | 2.22% | +1,637,951 | New | +$57.6M |
|
10
Apellis Pharmaceuticals
APLS
$3.48B
| $56.3M | 2.16% | 1,866,108 -200,000 | -10% | -$6.03M |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $56.3M | 2.16% | 500,000 -100,000 | -17% | -$11.3M |
|
12
Y-mAbs Therapeutics
YMAB
$388M
| $53.7M | 2.06% | 1,397,700 -176,983 | -11% | -$6.79M |
|
|
13
Zymeworks
ZYME
$1.12B
| $53.6M | 2.06% | 1,150,000 +600,000 | +109% | +$27.9M |
|
14
Stoke Therapeutics
STOK
$1.08B
| $51.5M | 1.98% | 1,537,807 -163,485 | -10% | -$5.48M |
|
15
Omeros
OMER
$283M
| $50.5M | 1.94% | 5,000,000 +2,225,000 | +80% | +$22.5M |
|
|
EIDX
16
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $50.2M | 1.93% | 993,185 -62,117 | -6% | -$3.14M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $45.7M | 1.76% | 275,000 -225,000 | -45% | -$37.4M |
|
|
VIE
18
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $44.5M | 1.71% | 1,585,000 +72,500 | +5% | +$2.04M |
|
|
RETA
19
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $43.8M | 1.69% | 450,000 +50,000 | +13% | +$4.87M |
|
20
Twist Bioscience
TWST
$1.63B
| $38M | 1.46% | 500,000 -52,849 | -10% | -$4.01M |
|
|
21
ALX Oncology
ALXO
$62.7M
| $36M | 1.38% | +971,770 | New | +$36M |
|
|
TRIL
22
DELISTED
Trillium Therapeutics Inc.
TRIL
| $35.5M | 1.37% | +2,500,000 | New | +$35.5M |
|
|
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
| $35.4M | 1.36% | 693,000 -27,397 | -4% | -$1.4M |
|
|
AGEN
24
Agenus
AGEN
$133M
| $34M | 1.31% | 8,500,000 -2,500,000 | -23% | -$10M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $32.5M | 1.25% | 500,000 -100,000 | -17% | -$6.5M |
|